期刊文献+

创新细菌疫苗的研究进展及挑战 被引量:4

Advances and challenges in research on innovative bacterial vaccines
原文传递
导出
摘要 细菌疫苗仍然是公共卫生防疫不可或缺的重要科学手段。近年来,医学、生物学、材料学等学科前沿领域的快速发展,不断推动已上市细菌疫苗品种升级优化,以满足人们日益增长的健康需求。与此同时,原创细菌疫苗在异常艰难的探索中取得诸多重大突破,以应对日趋严峻的超级耐药细菌。细菌比病毒颗粒大数10倍,且以独立生命体生存,基因组庞大,可形成芽孢、L形变异体、鞭毛、荚膜等特殊结构,其复杂的构造及高度的进化及繁衍能力,给细菌疫苗研制带来巨大挑战。前沿科学的不断突破与交叉融合,为解决上述挑战带来新的希望。本文对近年来创新细菌疫苗研发取得的突破和面临的挑战作一简要综述。 Bacterial vaccines remain an indispensable and essential scientific tool for public health.In recent years,rapid advances in medicine,biology,materials science and other subjects have driven the continuous upgrading and optimization of marketed bacterial vaccines to meet the increasing health needs of the population.At the same time,original vaccines have achieved many breakthroughs to deal with the growing number of super drug-resistant bacteria.Bacteria are tens of times bigger than viral particles.They survive as independent living organisms with large genomes,forming unique structures such as spores,L-phase variants,flagella and capsules.Their complex system and high ability to evolve and reproduce lead to number of challenges to bacterial vaccine development.The continuous breakthroughs and cross-fertilization of frontier science have brought new hope to solve the above challenges.In this review the advances and challenges in research on innovative bacterial vaccine in recent years are discussed.
作者 顾江 曾浩 邹全明 GU Jiang;ZENG Hao;ZOU Quan-ming(National Engineering Research Center of Immunological Products,Army Medical University,Chongqing 400038,China)
出处 《中国生物制品学杂志》 CAS CSCD 北大核心 2021年第9期1017-1022,共6页 Chinese Journal of Biologicals
关键词 创新细菌疫苗 进展 挑战 Innovative bacterial vaccine Progress Challenge
  • 相关文献

参考文献5

二级参考文献105

  • 1肖丽君,方艳辉,程露阳,孔健.脑膜炎奈瑟菌疫苗研制进展[J].微生物学免疫学进展,2006,34(1):58-60. 被引量:9
  • 2陈昌标,姜仁杰,马福宝,郑春早,胡高兵,熊慧玲.A群脑膜炎球菌多糖结合疫苗安全性和免疫原性观察[J].中国计划免疫,2006,12(5):403-405. 被引量:10
  • 3何莉,李荣成,李亚南,黄运能,姚群,袁曾麟,李凤祥,崔萱林,农艺,杨明.A+C群脑膜炎球菌多糖疫苗安全性和免疫原性的研究[J].中华流行病学杂志,2007,28(5):422-425. 被引量:20
  • 4伍传宏,王跃进,杭纪红,徐建芳,袁卫建,马福宝,陶红,荀鹏程.A、C、W135、Y群脑膜炎球菌四价多糖疫苗的安全性和免疫原性研究[J].实用预防医学,2007,14(6):1768-1770. 被引量:23
  • 5DantesR, MuY, BelflowerR, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011[J]. JAMA Intern Med, 2013, 173(21): 1970-1978. DOI: 10.1001/jamainternmed.2013.10423.
  • 6KleinE, SmithDL, LaxminarayanR. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005[J]. Emerg Infect Dis, 2007,13(12): 1840-1846. DOI: 10.3201/eid1312.070629.
  • 7WaltersM, LonswayD, RasheedK, et al. Investigation and control of vancomycin- resistant Staphylococcus aureus (VRSA): 2015 update[EB/OL]. (2015-04)[2016-08-08]. http://www.cdc.gov/hai/pdfs/VRSA-Investigation-Guide-05_12_2015.pdf.
  • 8HidayatLK, HsuDI, QuistR, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity[J]. Arch Intern Med, 2006, 166(19): 2138-2144. DOI: 10.1001/archinte.166.19.2138.
  • 9CataldoMA, TacconelliE, GrilliE, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis[J]. J Antimicrob Chemother, 2012,67(1): 17-24. DOI: 10.1093/jac/dkr442.
  • 10BaileyEM, RybakMJ, KaatzGW. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin[J]. Antimicrob Agents Chemother, 1991,35(6): 1089-1092.

共引文献408

同被引文献43

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部